Klinikum Chemnitz gGmbH | Oncological Center Chemnitz

Research site

(Unclaimed)

Location

Flemmingstraße 2, Chemnitz, Saxony, Germany

Site insights

Top conditions

Top treatments

Carboplatin

Azacitidine

Lenalidomide

Atezolizumab

Dexamethasone

Bevacizumab

Gemcitabine

cyclophosphamide

Daratumumab

vindesine

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

38 of 106 total trials

A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer (IMforte)

Study GO43104 is a Phase III, randomized, open-label, multicenter study of lurbinectedin in combination with atezolizumab compared with atezolizumab...

Enrolling

Small-Cell Lung Cancer

Drug: Atezolizumab

Drug: Lurbinectedin

A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden (Alternative-C)

The Alternative-C Trial is a prospective, multicenter Phase 2 Study to evaluate the efficacy of the chemotherapy-free combination of copanlisib and o...

Active, not recruiting

Follicular Lymphoma

Drug: Obinutuzumab

Drug: Copanlisib

A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer

This randomized, active-controlled, multicenter, open-label, Phase III study is designed to investigate the efficacy and safety of alectinib compared...

Active, not recruiting

Carcinoma, Non-Small-Cell Lung

Drug: Carboplatin

Drug: Vinorelbine

A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-10)

The purpose of this study is to compare the pharmacokinetics (processes by which drugs are absorbed, distributed in the body, and excreted) between t...

Enrolling

Relapsed or Refractory Multiple Myeloma

Drug: Teclistamab

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

A study designed tocompare progression-free survival (PFS) in participants with t(11;14)-positive MM treated with venetoclax in combination with dexa...

Active, not recruiting

Multiple Myeloma

Drug: Pomalidomide

Drug: Venetoclax

A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with end...

Enrolling

Early Breast Cancer

Drug: Endocrine Therapy of Physician's Choice

Drug: Abemaciclib

A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)

This study will evaluate the efficacy and safety of multiple therapies in participants with locally advanced, unresectable, Stage III NSCLC with elig...

Enrolling

Non-Small Cell Lung Cancer

Drug: Durvalumab

Drug: Entrectinib

A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer (METalmark)

The purpose of this study is to identify the recommended Phase 2 combination dose (RP2CD\[s\]) of the amivantamab and capmatinib combination therapy...

Active, not recruiting

Carcinoma, Non-Small-Cell Lung

Drug: Amivantamab

Drug: Capmatinib

A Study of Daratumumab

The purpose of this study is to provide ongoing access to study treatments for participants with multiple myeloma or smoldering multiple myeloma bene...

Enrolling

Multiple Myeloma

Drug: Carfilzomib

Drug: Daratumumab

A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy (VIALE-M)

This study will be conducted in two parts. Part 1 will be the Dose Confirmation portion to determine recommended Phase 3 dose (RPTD) of venetoclax in...

Active, not recruiting

Acute Myeloid Leukemia (AML)

Drug: Venetoclax

Drug: Azacitidine

A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer (SKYSCRAPER-06)

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of tiragolumab in combination with atezolizumab plus pemetrexed a...

Active, not recruiting

Non-small Cell Lung Cancer (NSCLC)

Drug: Tiragolumab Matching Placebo

Drug: Carboplatin

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

Patients with HER2-positive primary breast cancer (BC) who do not achieve complete response after appropriate neoadjuvant therapy are at higher risk...

Active, not recruiting

HER2-Positive Primary Breast Cancer

Residual Invasive Breast Cancer

Drug: DS-8201a

Drug: T-DM1

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis (VANTAGE)

The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching)...

Enrolling

PBC

Primary Biliary Cholangitis

Drug: Volixibat

Drug: Placebo

A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (B-FAST)

This is a phase 2/3, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immuno...

Enrolling

Non-Small Cell Lung Cancer

Drug: Docetaxel

Drug: Entrectinib

A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

This study is open to adults with a lung disease called Idiopathic Pulmonary Fibrosis (IPF). People can join the study if they are 40 years or older....

Active, not recruiting

Idiopathic Pulmonary Fibrosis

Drug: Placebo

Drug: BI 1015550

A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)

This study is open to adults with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs). People who have a form of PF-ILD other than Idiopathic...

Active, not recruiting

Lung Diseases, Interstitial

Drug: BI 1015550

Drug: Placebo

A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (BRUIN CLL-322)

The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm...

Enrolling

Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia

Drug: Venetoclax

Drug: Rituximab

Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)

This phase I/II clinical trial evaluates the safety and efficacy of the combined administration of midostaurin and gemtuzumab ozogamicin in the frame...

Enrolling

Acute Myeloid Leukemia

Drug: MODULE: conventional chemotherapy (Cytarabine+Daunorubicin) in combination with midostaurin+GO

Drug: MAGMA-trial: conventional chemotherapy (AraC+DNR)+Midostaurin

Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)

Brief Summary:The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of Tumor Treating Fields (TTFie...

Active, not recruiting

Pancreas Adenocarcinoma

Drug: nab paclitaxel

Drug: Gemcitabine

Frontline Asciminib Combination in Chronic Phase CML (CMLXI)

Adult male and female patients with newly diagnosed Philadelphia chromosome positive (Ph+) and/or BCR-ABL1 positive CML can be included in the study...

Active, not recruiting

Chronic Myeloid Leukemia

Drug: Asciminib

Drug: Nilotinib 300 mg